News - Inlyta

Filter

Current filters:

Inlyta

Popular Filters

Regulator backs Inlyta, Lucentis and Xtandi for NHS Scotland, but not Bosulif

12-11-2013

The Scottish Medicines Consortium (SMC) revealed this morning (November 12) that it has accepted US drug…

Astellas PharmaBosulifEuropeInlytaLucentisNovartisOncologyOphthalmicsPfizerPharmaceuticalRegulationXtandi

NICE denies NHS use of Pfizer's Inlyta for patients with terminal kidney cancer

28-03-2013

In a second disappointment from the agency this week, US drugs behemoth Pfizer (NYSE: PFE) Ltd expressed…

EuropeInlytaOncologyPfizerPharmaceuticalPricingRegulation

German drugs watchdog finds "hint of considerable added benefit" for Pfizer's Inlyta

09-01-2013

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the added benefit…

BayerEuropeInlytaNexavarOncologyPfizerPharmaceuticalPricingRegulation

Pfizer's Inlyta misses primary endpoint in Ph III kidney cancer trial

18-10-2012

US drugs behemoth Pfizer (NYSE: PFE) revealed yesterday that a Phase III study of Inlyta axitinib) did…

InlytaOncologyPfizerPharmaceuticalResearch

European approval for Pfizer's kidney cancer drug Inlyta

05-09-2012

The European Commission yesterday granted marketing authorization for Pfizer's (NYSE: PFE) Inlyta (axitinib)…

EuropeInlytaOncologyPfizerPharmaceuticalRegulation

FDA OKs Pfizer’s Inlyta and accepts NDA for bosutinib

30-01-2012

The US Food and Drug Administration on Friday approved global pharma behemoth Pfizer’s (NYSE: PFE)…

bosutinibInlytaNorth AmericaOncologyPfizerPharmaceuticalRegulation

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top